Health Current

healthcurrent.org

Arizona Health-e Connection Is Now Health Current Powering the future of healthcare with more complete information. Health Current is the health information exchange (HIE) that helps partners transform care by bringing together communities and information across Arizona. More complete information is more meaningful and leads to better care and better outcomes. It makes healthcare transformation possible. That’s why we’ve worked for more than ten years to become Arizona’s primary resource for information technology and exchange, integrating information with the delivery of care to improve the health and wellbeing of individuals and communities. As we’ve grown, our core goal has remained the same: help providers use information technology to improve people’s lives.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

BIO-TECHNE SIGNS LICENSE AGREEMENT WITH LUMINARY THERAPEUTICS FOR THE USE OF TCBUSTER™ FOR THE MANUFACTURING OF GENE-MODIFIED CELL THERAPIES

Bio-Techne | February 25, 2021

news image

Bio-Techne Corporation today declared the signing of a license agreement with Luminary Therapeutics for the utilization of TcBuster™ for the manufacturing of gene-modified cell therapies. TcBuster is Bio-Techne's proprietary non-viral transposon-based gene delivery system used to advance cell therapy manufacturing. Under the provisions of this agreement, Bio-Techne grants Luminary Therapeutics a non-exclusive license for TcBuster. Luminary Therapeutics will utilize TcBus...

Read More

AI

EUREKARE AND DNALYTICS FORM PARTNERSHIP TO DEVELOP A PROPRIETARY AI PLATFORM

eureKARE | July 07, 2021

news image

eureKARE, a pioneering new company focused on financing and building next-generation biotechnology companies in the disruptive fields of the microbiome and synthetic biology, today announced an agreement with DNAlytics, a Belgian company applying data sciences to healthcare, to develop eureKARE's proprietary Artificial Intelligence (AI) platform to support its Biotech start-upstart-up studios, eureKARE. Unlike conventional start-upstart-up incubation methods, which begin with ...

Read More

Industry Outlook

SOMALOGIC PARTNERS WITH CITOGEN TO EXPAND AUTHORIZED SITE PROGRAM IN EUROPE

Globenewswire | June 13, 2023

news image

SomaLogic, Inc., a leader in proteomics technology, announced their collaboration with Citogen, the Longwood Group’s customer services and support unit, to establish the company’s first authorized site in Spain. As part of the agreement, Citogen will offer the 7,000-plex SomaScan® Assay and provide SomaScan data to their customers in Southern Europe supporting biological research across an array of disciplines including clinical research, population health studies and nutri...

Read More

LIMINAL BIOSCIENCES EXPANDS R&D PIPELINE WITH NOVEL PRECLINICAL PROGRAM FOR EOSINOPHILIC-RELATED DISEASES

Liminal BioSciences Inc. | July 20, 2020

news image

Liminal BioSciences Inc. (Nasdaq: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that it has acquired all of the issued and outstanding shares in the capital of Fairhaven Pharmaceuticals Inc. ("Fairhaven"), thus acquiring a preclinical research program of small molecule antagonists. Investigational therapies developed in this program target a key chemoattractant and activator of eosinophils, wh...

Read More
news image

Cell and Gene Therapy

BIO-TECHNE SIGNS LICENSE AGREEMENT WITH LUMINARY THERAPEUTICS FOR THE USE OF TCBUSTER™ FOR THE MANUFACTURING OF GENE-MODIFIED CELL THERAPIES

Bio-Techne | February 25, 2021

Bio-Techne Corporation today declared the signing of a license agreement with Luminary Therapeutics for the utilization of TcBuster™ for the manufacturing of gene-modified cell therapies. TcBuster is Bio-Techne's proprietary non-viral transposon-based gene delivery system used to advance cell therapy manufacturing. Under the provisions of this agreement, Bio-Techne grants Luminary Therapeutics a non-exclusive license for TcBuster. Luminary Therapeutics will utilize TcBus...

Read More
news image

AI

EUREKARE AND DNALYTICS FORM PARTNERSHIP TO DEVELOP A PROPRIETARY AI PLATFORM

eureKARE | July 07, 2021

eureKARE, a pioneering new company focused on financing and building next-generation biotechnology companies in the disruptive fields of the microbiome and synthetic biology, today announced an agreement with DNAlytics, a Belgian company applying data sciences to healthcare, to develop eureKARE's proprietary Artificial Intelligence (AI) platform to support its Biotech start-upstart-up studios, eureKARE. Unlike conventional start-upstart-up incubation methods, which begin with ...

Read More
news image

Industry Outlook

SOMALOGIC PARTNERS WITH CITOGEN TO EXPAND AUTHORIZED SITE PROGRAM IN EUROPE

Globenewswire | June 13, 2023

SomaLogic, Inc., a leader in proteomics technology, announced their collaboration with Citogen, the Longwood Group’s customer services and support unit, to establish the company’s first authorized site in Spain. As part of the agreement, Citogen will offer the 7,000-plex SomaScan® Assay and provide SomaScan data to their customers in Southern Europe supporting biological research across an array of disciplines including clinical research, population health studies and nutri...

Read More
news image

LIMINAL BIOSCIENCES EXPANDS R&D PIPELINE WITH NOVEL PRECLINICAL PROGRAM FOR EOSINOPHILIC-RELATED DISEASES

Liminal BioSciences Inc. | July 20, 2020

Liminal BioSciences Inc. (Nasdaq: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that it has acquired all of the issued and outstanding shares in the capital of Fairhaven Pharmaceuticals Inc. ("Fairhaven"), thus acquiring a preclinical research program of small molecule antagonists. Investigational therapies developed in this program target a key chemoattractant and activator of eosinophils, wh...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us